Thank you for submitting your manuscript for consideration by the EMBO Journal. It has now been seen by three referees whose comments are shown below. Given the referees' positive recommendations, I would like to invite you to submit a revised version of the manuscript, addressing the comments of all three reviewers.
Thank you for submitting your manuscript for consideration by the EMBO Journal. It has now been seen by three referees whose comments are shown below. Given the referees' positive recommendations, I would like to invite you to submit a revised version of the manuscript, addressing the comments of all three reviewers.
You show HDAC6-dependent regulation of vessel formation during zebrafish embryogenesis and in mice. α-tubulin deacetylase activity and ubiquitin-binding activity of HDAC6 appear not to be required for cell migration and sprouting. Cortactin is a deacetylation target of HDAC6 and it appears to mediate endothelial cell migration and vessel formation.
Referee 1 found the zebrafish data interesting, but noted the partial effect of siRNA in mouse. The referee requests more quantitative Western blots and a number of controls. Importantly, the referee finds the tubulin acetylation data not compelling. Finally, the HDAC6 and cortactin co-localiziation is not deemed to be definitive.
Referee 2 also noted the more limited data in mouse. In particular, the referee suggest that you analyze vessel formation and angiogenesis in the mouse model, testing the role of HDAC6 in tumorinduced angiogenesis in the mouse model. Importantly, the referee discusses apparent miscitation of a number of papers. Furthermore, the referee is not convinced by the independence of tubulin deacetylation and s/he suggests that you need to show that the mutant can in fact deacetylate cortactin while it remains inactive towards acetylated tubulin. In fact, the referee finds that the tubulin deacetylase assays are not definitive.
As an aside, the referee suggests that the HDAC6 upregulation by hypoxia could be moved to supplementary information to streamline the presentation.
Referee 3 also highlights the discrepancy between zebrafish and mouse and wants evidence for redundancy by HDAC10. The referee suggests to show HDAC10 also targets cortactin and that it rescues HDAC 6 loss of function. The referee recommends to present a rescue of HDAC6 morphants with cortactin 9KR. Like referee 1, the HDAC6-cortactin co-localization is not deemed to be definitive.
Please be aware that it is EMBO Journal policy to allow only a single round of revision, and acceptance of your manuscript will therefore depend on the completeness of your responses in this revised version.
When preparing your letter of response to the referees' comments, please bear in mind that this will form part of the Review Process File, and will therefore be available online to the community. For more details on our Transparent Editorial Process, please visit our website: http://www.nature.com/emboj/about/process.html
We generally allow three months as standard revision time. As a matter of policy, competing manuscripts published during this period will not negatively impact on our assessment of the conceptual advance presented by your study. However, we request that you contact the editor as soon as possible upon publication of any related work, to discuss how to proceed. If you require more than three months for the revision, please discuss this with us in advance.
Thank you for the opportunity to consider your work for publication. I look forward to your revision.
Yours sincerely, Editor
The EMBO Journal
------------------------------------------------REFEREE COMMENTS
Referee #1:
The Urbich and Dimmeler group presents data on the HDAC6-dependent regulation of vessel formation during zebrafish embryogenesis and in mice. This is a highly interesting topic. This idea is based on the fact that some of the HDAC inhibitors impact angiogenesis and it was previously reported that HDAC5 and HDAC7 have an important function in VEGF-induced angiogenesis in vitro. Furthermore, the stability of Hif-1alpha protein is up-regulated in hypoxia, leading to VEGF expression to form new vessels. The authors focused on the possible HDAC6 function in vessel formation. To show the relationships between HDAC6 and vessel formation, the author used two experimental tools, one is endothelial cell sprouting and migration in vitro, and the other is zebrafish embryogenesis. Several data on zebrafish vessel formation are exciting. However, somewhat disappointingly, siRNA knockdown data showed only a partial phenotype.
The authors found that α-tubulin deacetylase activity and ubiquitin-binding activity of HDAC6 is not required for cell migration and sprouting. Furthermore, they show that the deacetylation target of HDAC6 is cortactin and that cortactin has an important role in endothelial cell migration and vessel formation. Those results should be of interest to understand the physiological function of HDAC6.
In sum, this work represents some biological and developmental analysis of HDAC6 involving in the interaction and deacetylation of cortactin, which regulates endothelial cell migration and sprouting.
However, at this point the authors need to solidify some of the evidence presented and several points should be addressed.
Major points:
Several western blots do not appear to have been quantified very carefully; some of the differences visible appear to be minor and it is not clear how representative they are.
In Figure 1D , an example of non-treated cells should be presented, as it is not clear to what extent the effect seen is due to the downregulation of HDAC6 vs treatment with siRNA in general. The quantification of that figure is also not clear. Figure 3F , H and I: the picture is not convincing and better pictures should be provided. In Fig. 3F , pictures of non-treated cells should also be provided, so that one can see where the baseline is.
In supplementary Figure 3D it is argued that HDAC6 was significantly up-regulated under hypoxic condition. However, the difference is slight at RNA level and the western blot is not quantitative. Figure 4 : the data on tubulin acetylation (A, B, C) are not convincing. It is not clear to this reviewer how transfection of WT HDAC6 does not have more effect on tubulin acetylation than the mock transfection ( Fig. 4B ). Yet, based on this data the authors draw conclusions on the deacetylase activity potential of various mutants. The authors should present a new set of data, where they can convincingly demonstrate the activity of WT and mutant HDAC6 and relate it to effect -or absence of effect-on sprouting etc... How reliable is the measurement of cumulative sprout length? Figure 5A : the quality of the photographs is not sufficient to examine the co-localization of HDAC6 and cortactin. Higher magnification should also be provided. Similarly, supplementary figures 7A/B are not very clear. P6; In Fig.1C and D, the author measured the cumulative sprout length in a three dimensional spheroid assay. In Fig.1C , siHDAC6 I seems to be most effective (decreased), but in Fig.1D, I could not see the difference of spheroid in all the pictures. Moreover, in Fig.1E , why did they show siHDAC6 II knockdown phenotype in this figure (why not siHDAC6 I?)? P7-8; In Fig.2A and B, can we exclude the possibility that exon 5 skipped transcripts did not appear? P10; In Fig. 4G , can we detect V5-tagged HDAC6 wt in the center lane of this blot?
In Fig.5C , upper cortactin blot, cortactin signal is not clear because of high background signals. Again, in Fig.5C , lower panel, cortactin blot, which is immunoprecipitated by HDAC6 is not clear. P13 lane 7; "HIF-1a" should be "HIF-1 alpha". P13 lane 8; vascular smooth muscle cells (VSMCs) P16 lane 11; "Our results demonstrate, that" is "Our results demonstrate that". P17 lane 4 and lane7; "15 dyne/cm2" or "20 dyn/cm2", which is correct? P17 lane 7; "in flow channels (µ-Slide I 0.4 Luer combined with the ibidi pump system, ibidi, Martinsried, Germany)" This explanation should be added in Supplemental material and methods. P17 lane11 and 13; "HIF-1a" is "HIF-1 alpha". P23 lane 5; "for 4 d and " is "for 4 days and" P24 "Statistical analysis" paragraph should be included in "Matrigel plug assay".
All immunofluorescence pictures should represent scale bar.
Figure legends: Fig. 1E ; Black bar shows siScr control, and white bar shows siHDAC6 II. Fig. 2A ; "danio rerio HDAC6 mRNA" is "Danio rerio HDAC6 mRNA". Scientific name in Latin should be italic. Fig. 3A ; "After 7 d HUVEC were" is "After 7 days HUVEC were". Fig. 4D ; "for 6 d followed by" is "for 6 days followed by". Kaluza and colleagues uncovered a role for HDAC6 in endothelial cell migration and sprouting. Investigation of the mechanisms underlying this activity of HDAC6 pointed to HDAC6-mediated control of cortactin acetylation as a key event.
The major interest of this report comes from the investigation of the activity of HDAC6 in endothelial cells in a physiological setting, mostly using the zebrafish system but also, in a much more restricted manner, in the mouse.
In order to strengthen the conclusions of this work and to better characterize the underlying mechanism, the authors should consider the points detailed below. Additionally, important publications on HDAC6, including some from the co-authors' laboratory, are misleadingly presented. The authors need to be more rigorous in presenting the previously published data.
Specific points:
1 -Based on the use of HDAC6 mutants, the authors concluded that the role of HDAC6 in endothelial cell migration and angiogenesis is independent of its tubulin-deacetylase activity. This conclusion is solely based on the use of HDAC6 mutants each bearing an inactivating mutation in one of the two catalytical domains, one of them specifically inactivating its tubulin-deacetylase (TDAC) activity.
First of all, the authors need to show that, according to their hypothesis, this particular mutant could in fact deacetylate cortactin while it remains inactive towards acetylated tubulin.
Although the authors are aware of the fact that the exact nature of the contribution of each of the two catalytic domains of HDAC6 in its substrate-specific activity is controversial (see the discussion section), they have based their model only on one of the two conflicting result sets.
Additionally, the way the literature is presented in table A (supplementary Fig. 6 ) is simply unacceptable. For instance the reference "Grozinger PNAS 1999" is given for both histone and TDAC activity of HDAC6, while in 1999 the tubulin-deacetylase activity of HDAC6 was not known. This reference (Grozinger et al. 1999 ) even does not correspond to the first report describing the HDAC activity of HDAC6.
There are other misleading presentations of the literature with this regard. The first indication regarding the requirement of both catalytic domains in the TDAC activity of HDAC6 came from Zhang et al., 2003 and not Zhang et al., 2006 (page 14) . Zhang et al. 2003 , like in the present study, used HDAC6 bearing a single mutation in each domain (H216A and H611A), and showed in each case a loss of global TDAC activity (please see Fig. 6 of the corresponding paper). Therefore, the claim that "multiple mutations could explain the discrepancy" (page 14 bottom) is based on an erroneous presentation of the literature.
The authors have also themselves tested the TDAC activity of their mutants shown in Fig. 4B and C. The approach used is the ectopic expression of HDAC6 (wt and mutants) and the measurement of tubulin acetylation by western blot, which is far from being a sensitive and conclusive assay. Blots show modest effects and quantifications based on blots are questionable.
Since the authors make such a strong case in excluding a role for tubulin-deacetylation in the HDAC6-stimulated migration of endothelial cells, it becomes very important to carefully control this point.
The western blot is not a sensitive and reliable method to measure HDAC6 catalytic activity. Signals are often saturated and the normalizations are not reliable.
In order to support a role for HDAC6 in cortactin deacetylation but not in tubulin deacetylation, the authors should set up convincing assays and show the activity of wt HDAC6 and their mutants towards both tubulin and cortactin.
Referee #3: Kaluza D. et al demonstrate that HDAC6-mediated deacetylation of cortactin is essential for developmental angiogenesis in zebrafish. The role for HDAC6 (Class IIb) in angiogenesis has been unclear, while those of other HDACs have been recently unraveled. The author's group has reported that HDAC5 (Class IIa) function as a repressor of angiogenic genes in endothelial cells. This study, therefore, becomes the first study which reveals the essential role of HDAC6 (Class IIb) for angiogenesis in zebrafish. By identifying a substrate of HDAC6, cortactin, the authors clarified the essential role for HDAC6 in vascular development.
This study was thoroughly and intellectually performed to understand the role of HDAC6 for vascular development except one contradiction that HDAC6 is required for developmental angiogenesis in zebrafish but not in mice. Although the authors discuss this point in the discussion section, only discussion is not sufficient. The readers might not agree with the conclusion they came to in the present manuscript. The authors do not fully and clearly explain why there is a remarkable difference of developmental angiogenesis in zebrafish depleted of HDAC6 and HDC6 knockout mice. This point should be addressed to prove that the authors' claim is correct.
Major points:
1. Why are vascular defects observed in only zebrafish lacking HDAC6 but not in the mice lacking HDAC6? In both zebrafish depleted of HDAC6 and HDAC6 knockout mice, hyper-acetylation of alpha tubulin is conserved. The authors claim that the vascular defects are ascribed to the accumulation of acetylated cortactin in zebrafish depleted of HADC6. If the HDAC6-mediated deacetylation is essential for angiogenesis and universal among several species, the HDAC6 knockout mice should exhibit abnormal developmental angiogenesis. If another Class IIb HDAC, HDAC10, compensates the defect of HDAC6, the authors at least must show that HDAC10 can deacetylate cortactin. Are the defects of blood vessels in HDAC6 morphants can be rescued by the over expression of HDAC10? If the authors can prove the compensatory role of HDAC10 for the HDAC6, the main claim might be supported. Although the best way is to develop HDAC6 and HDAC10 double knockout mice, at least the authors need to show HDAC10-mediated deacetylation of cortactin and to inject HDAC10 mRNA into HDAC6 morphants to see whether HDAC10 has a compensatory mechanism.
2. The cell images should be replaced with the clearer images and enlarged images; e.g., all of the iamges for the cells should be enlarged. In addition, the untreated cells and those treated with siRNA for HDAC6 should be examined by immunohistochemistry using anti-HDAC6 antibody. The reader can not see the colocalization of HDAC and cortactin in the cytoplasm. Figure 5A merely shows that both are in the cytoplasm. It does not reveal that they are colocalized in the cytoplasm. The arrows in the merged image do not point to the colocalized HDAC6 and cortactin. The cell-cell contacts should be enlarged to stress the colocalization of both molecules.
3. To prove the real substrate of HDAC6 is cortactin that accounts for the defects of blood vessels in HDAC6 morphants, the authors should perform the rescue experiment using cortactin 9KR in HDAC6 morphants.
Minor points:
(i) Figure 2A is unnecessary. The readers easily understand the morpholinos which are popular in the zebrafish studies. This can be moved to the supplementary information.
(ii) Why did the authors need to immunostain fli1:egfp Tg fish using anti-GFP antibody instead of directly visualizing the green fluorescence? The original GFP images should be shown as the results.
(iii) Why did the author change the order of loading samples in Figure 2C ? The order should be CoMo 5 ng, HDAC6 TB-Mo 2 ng, HDAC6 TB-Mo 5 ng, and HDAC6 SB-Mo 5 ng, according to the orders in other Figures ( Figure 2C , 2F and 2G).
(iv) Figure 3H , in the legend, the authors describe that this is representative image. What is this representative of? (v) Figure 3I (the image of H&E staining) should be enlarged; otherwise the readers cannot distinguish the H-stained cells in the E-stained matrigel. Reply to reviewer #1:
We thank the reviewer for her / his helpful suggestions. • We replaced the Western blot in Figure 4A and included a quantification in Fig. 1 for the reviewer.
• We changed the statement for Figure 4B and provided a new series with modified experimental conditions to show the activity of the HDAC6 constructs towards α-tubulin (please see major comments point 5) • With regard to Supplementary Fig. 1B , we changed our statement (please see minor comments point 8)
• With regard to Supplementary Fig. 3D , we replaced the Western blot showing a more representative blot. Figure 1D ,
2) In

an example of non-treated cells should be presented, as it is not clear to what extent the effect seen is due to the downregulation of HDAC6 vs treatment with siRNA in general.
As suggested by the reviewer, we included untreated and vehicle-(only transfection reagent) treated cells in Figure 1B /C of the revised manuscript. We did not observe a statistical difference between untreated, vehicle-treated or control siRNA-treated cells regarding the sprouting capacity.
The quantification of that figure is also not clear.
To quantify the cumulative sprout length per spheroid, every sprout from 10 -15 spheroids of each experiment was assessed. Then, the total sum of all sprout lengths from each of these 10 -15 spheroids was divided by the number of spheroids examined (i.e., 10 -15) in order to provide the mean cumulative sprout length per spheroid. The experiments have been reproduced at least n=3 times and thus include quantification of more than 30 spheroids. The absolute values of mean cumulative sprout length per spheroid in micrometer are given in Figure 1B of the revised manuscript.
3) Figure 3F, H and I: the picture is not convincing and better pictures should be provided. In Fig. 3F, pictures of non-treated cells should also be provided, so that one can see where the baseline is.
According to the reviewer's suggestion, we changed the representative pictures in the original Figures 3H and 3I ( Figure 3F and G of the revised manuscript). However, in our opinion, original Figure 3F (now Figure 3D ) representatively demonstrates a decreased size and perfusion of CD34+ vessels in animals treated with shHDAC6 cells. Furthermore, the pictures of Figure 3F are comparable to pictures of the original study which established this assay (Alajati et al., 2008) .
In addition, the reviewer requested pictures of non-treated cells to compare non-treated cells to control shRNA treated cells. Because we did not use untreated cells in our initial study, we can not provide results with untreated cells in vivo. To provide this additional second control group, we would have to repeat the entire experiment with untreated cells and the two shRNA groups, which will not be supported by the ethics review boards of animal care.
However, we have performed in vitro experiments to address the reviewer's comment. As shown in Figure 2A /B for the reviewer, treatment of HUVEC with shControl virus does not affect sprouting and network formation compared to untreated HUVEC in vitro, whereas the shHDAC6 virus significantly reduces sprouting in the spheroid assay and decreases tube formation to a similar extent compared to the siRNA experiments in Supplementary Figure 1G .
In addition, please note that the values of microvascular density and perfusion in the shControl group in our study are in a similar range compared to untreated HUVEC shown by our collaborators in the original publication of this assay ( (Alajati et al., 2008) ; please see Figure 2C for the reviewer at 20 days compared to 21 days in our experimental setting). Figure 3D it is argued that HDAC6 was significantly up-regulated under hypoxic condition. However, the difference is slight at RNA level and the western blot is not quantitative.
4) In supplementary
We agree with the reviewer that the upregulation of HDAC6 by hypoxia is modest. In accordance with our data, it was recently shown that HDAC6 mRNA is slightly but significantly upregulated (approximately 1.3 fold; comparable to our results) under hypoxic conditions in rat hearts (Lemon et al., 2011) . Interestingly, HDAC6 can affect HIF-1 alpha stability and target gene transcription (Kong et al., 2006) . However, in HUVEC we did not observe a regulation of HIF-1 alpha dependent genes by HDAC6 under hypoxic conditions (data not shown). Therefore, we discussed these findings as follows (page 19, para 1): "Interestingly, hypoxia up-regulates HDAC6 mRNA and protein expression in endothelial cells, which is in line with a recent study showing that the HDAC6 mRNA level is elevated in hypoxia induced hypertrophic hearts (Lemon et al., 2011) ."
5) Figure 4: the data on tubulin acetylation (A, B, C) are not convincing. It is not clear to this reviewer how transfection of WT HDAC6 does not have more effect on tubulin acetylation than the mock transfection (Fig. 4B). Yet, based on this data the authors draw conclusions on the deacetylase activity potential of various mutants. The authors should present a new set of data, where they can convincingly demonstrate the activity of WT and mutant HDAC6 and relate it to effect -or absence of effect-on sprouting etc...
As suggested by the reviewer, we changed Figure 4A and provide a new representative Western blot. A quantification of three independent experiments is shown in Figure 1 for the reviewer. With regard to original Figure 4B /C, we noticed that inhibition of HDAC6 by tubacin leads to a 25-fold increase of the acetylation of α-tubulin in HUVECs (Supplementary Figure 6A and B) indicating that under basal condition the majority of tubulin is already deacetylated. We suggest that this is the reason why overexpression of HDAC6 constructs does only modestly affect α-tubulin acetylation under basal conditions. Therefore, we changed our statement in the results section (page 9, para 1): "Under basal conditions overexpression of these constructs only modestly affect α-tubulin acetylation (Fig. 4B) , probably due to the low levels of acetylated α-tubulin in HUVEC."
However, overexpression of some of these constructs (namely HDAC6 wt, HDAC6 H216A and HDAC6 H611A) significantly increases endothelial sprouting and the deacetylation of cortactin under basal conditions ( Figure 4E and 5D of the revised manuscript). Therefore, it is more likely that the regulation of angiogenesis is mediated by cortactin rather than by tubulin deacetylation. To confirm the activity of these constructs towards α-tubulin, we changed the experimental settings. Therefore, we inhibited HDAC6 in HUVEC by 2.5 µM tubacin and determined in a pilot experiment the kinetics of tubulin deacetylation after washout of the inhibitor. Within the first 60 min the acetylation of tubulin drops only moderately while after 180 min the acetylation of tubulin is completely gone (Figure 3 for the reviewer). We repeated the experiment with HUVEC overexpressing different HDAC6 constructs, taking lysates at 90 min. To streamline our presentation, we focused on the series of single mutations in either or both of the deacetylation domains. HUVEC overexpressing HDAC6 wt and HDAC6 H216A show an increased deacetylation of tubulin at 90 min compared to mock transduced or HDAC6 H611A and HDAC6 H216/611A transduced cells ( Figure 4C ), confirming that only HDAC6 wt and HDAC6 H216A exhibit α-tubulin deacetylation activity.
How reliable is the measurement of cumulative sprout length?
The spheroid assay was established and characterized in detail by Augustin and colleagues (Korff & Augustin, 1999) . The measurement of the cumulative sprout length is a sensitive and reliable method to analyze sprouting angiogenesis in vitro and it is used as a standard assay in angiogenesis research (Bonauer et al., 2009; Meyer et al., 1999; Potente et al., 2007; Takeda et al., 2007) . As outlined above, we evaluated sprouting of more than 10 spheroids/experiment and reproduced the experiments more than 3 times (total >30 spheroids per data point presented) allowing a robust statistical analysis of the data. In addition to the cumulative sprout length, it is possible to measure the number of sprouts and the number of branch points per spheroid as additional parameters. As shown in Supplementary Figure 1E /F, HDAC6 silencing by siRNA also significantly decreased the number of sprouts and branch points per spheroid. Of course, this assay mimics only in part the angiogenic process but the three dimensional cytokine and matrix environment at least partially mimics the angiogenic sprouting in vivo and may be favorable compared to 2 dimensional assays. Figure 5A: As suggested, we changed the photographs for all co-localization studies showing higher magnifications in Figure 5A and Supplementary Figure 7 of the revised manuscript.
6)
7) Minor comments; P6 line4; ~in endothelial cells (EC). Abbreviation should be added.
We added the abbreviation (page 3, para 2). As suggested by the reviewer, we included the siRNA transfection protocol as well as the siRNA sequences in the main Material and Methods section (page 20, para 2). In addition, we moved the original Figure 1B to the supplements as Supplementary Figure 1D . Fig.1C We changed the representative pictures ( Figure 1C of the revised manuscript) so that they better reflect data shown in Figure 1D of the original manuscript (now Figure 1B) . Please note that there is no statistical significance between the single HDAC6 siRNAs regarding endothelial sprouting. As suggested by the reviewer, we changed Figure 1E to show cell migration after siHDAC6 I and siHDAC6 II transfection under basal conditions ( Figure 1D of the revised manuscript). Fig.2A and B, can we exclude the possibility that exon 5 skipped transcripts did not appear?
10) P6; In
11) P7-8; In
We can not fully exclude the possibility that besides non-skipping of intron 5 there is an additional skipping of exon 5. Because we did not detect a band at the calculated size, we concluded that this splicing event is not preferred. However, if the mRNA lacking exon 5 is highly instable we would not be able to detect this splicing event. Irrespective of the exact mechanism by which the morpholino affects HDAC6 mRNA, we observed a profound silencing of HDAC6 on protein level as shown in Figure 2B . Please note that the effects on vessel formation in zebrafish was confirmed by an additional independent approach to inhibit HDAC6 expression (see Figure 2E ).
12) P10; In Fig. 4G, can we detect V5-tagged HDAC6 wt in the center lane of this blot?
As suggested, we changed the Western blot in Figure 4G showing only the V5-tagged HDAC6 overexpression. Fig.5C In former Figure 5C (Supplementary Figure 8B , upper blot) the overexpression was detected with an antibody, which additionally detects endogenous cortactin. Thus, in the control the band reflects the expression of endogenous cortactin. We apologize for the high background of cortactin immunoprecipitated by HDAC6 in the lower panel. Although we tried to reduce the background by different approaches, we were unable to improve the quality of the Western blots.
13) In
14) P13 lane7; "HIF-1a" should be "HIF-1 alpha".
We changed the wording.
15) P13 lane8; vascular smooth muscle cells (VSMCs)
We added the suggested wording.
16) P16 lane 11; "Our results demonstrate, that" is "Our results demonstrate that".
17) P17 lane4 and lane7; "15 dyne/cm2" or "20 dyn/cm2", which is correct?
The name of the si unit is dyne while the abbreviation is dyn. Therefore we changed the wording to dyn. We removed this information to the Supplemental material and methods.
18) P17 lane7; "in flow channels
19) P17 lane11 and 13; "HIF-1a" is "HIF-1 alpha".
20) P23 lane5; "for 4 d and " is "for 4 days and"
21) P24 "Statistical analysis" paragraph should be included in "Matrigel plug assay".
Lectin-positive structures were counted manually in five microscopic fields in three different sections of each plug (5x/0.25 objective) using a computer-assisted fluorescence microscope (Axiovert 100 M equipped with AxioCam camera, Carl Zeiss, Jena). The average vessel number per plug was calculated and the mean value for both matrigel plugs for each mouse was taken for the statistical analysis using an unpaired student´s t-test.
22) All immunofluorescence pictures should represent scale bar.
We included scale bars for the representative images. Fig. 1E ; Black bar shows siScr control, and white bar shows siHDAC6 II.
23) Figure legends;
Because the figure was changed showing only the basal migration level the figure legend was changed accordingly. Fig. 2A ; "daniorerio HDAC6 mRNA" is "Daniorerio HDAC6 mRNA". Scientific name in Latin should be italic. Fig. 3A ; "After 7 d HUVEC were" is "After 7 days HUVEC were". Fig. 4D ; "for 6 d followed by" is "for 6 days followed by".
We changed the wording
24) Fig. 5E; They showed endogenous cortactinimmunoprecipitation. How about HDAC6 immunoprecipitation result?
A recent study by Zhang and colleagues already showed that endogenous cortactin coimmunoprecipitates with endogenous HDAC6 in HeLa cells (Zhang et al., 2007) . Therefore, we did not repeat the experiment. Fig. 5F , "* represent unspecific" should be "Asterisk represent unspecific".
25) P37 lane6;
We changed the wording according to the recommendations.
Reply to reviewer #2:
We thank the reviewer for her / his helpful suggestions. In addition to HDAC6 mutants, we used the HDAC6-specific inhibitor tubacin, which mainly affects the tubulin deacetylation activity of HDAC6. We observed a strong increase of tubulin acetylation in HUVEC (25-fold) after treatment (Supplementary Figure 6A and B), whereas tubacin treatment did not affect cortactin acetylation ( Figure 5D of the revised manuscript). However, despite a profound increase in tubulin acetylation, we did not observe an effect on endothelial cell migration, sprouting and tube formation after incubation by tubacin (Supplementary Figure 6C) , indicating that the acetylation of tubulin does not directly affect endothelial cell functions.
During revision of this manuscript, Li et al. demonstrate that pharmacological inhibition of HDAC6 with tubacin and silencing by siRNA inhibits HUVEC cell migration, tube formation and sprouting angiogenesis (Li et al., 2011 ). However, as described above, we did not observe a phenotype by tubacin treatment. We used the well described concentration range of 2.5-10 µM in our experiments. Li et al. do not provide the concentration used for their experiments. Therefore, differences in the experimental conditions or the concentration of tubacin used may explain the differential experimental outcome.
First of all, the authors need to show that, according to their hypothesis, this particular mutant could in fact deacetylatecortactin while it remains inactive towards acetylated tubulin.
As suggested by the reviewer, we show the effect of the different constructs for α-tubulin deacetylation (Fig. 4C of the revised manuscript) and for cortactin deacetylation ( Fig 5D of We agree with the reviewer and modified the discussion section presenting all current literature regarding the catalytic activity of the HDAC6 H216/611A deletion series (please see discussion below). Fig. 6) (Grozinger et al. 1999 ) even does not correspond to the first report describing the HDAC activity of HDAC6.
Additionally, the way the literature is presented in table A (supplementary
We apologize for the misleading citation. In this table, we only cited publications in which some or all of these constructs were used to assess the tubulin and histone deacetylation activity directly. We changed the table discussing the controversial results from three different laboratories, which directly assessed the activity of these mutants (see discussion below). We apologize for the improper citation of the literature regarding the effect of different HDAC6 mutations on tubulin and histone deacetylation. Indeed, there are currently 5 publications from three different research groups analyzing the effect of single or multiple mutations in the two deacetylation domains of HDAC6. In 1999, the group of Stuart Schreiber showed that HDAC6 wt, and the single mutation constructs HDAC6 H216A and HDAC6 H611A possess histone deacetylation activity, while HDAC6 H216/611A shows no activity using immunoprecipitated HDAC6 and in vivo isolated [ 3 H]-acetylated histones (Grozinger et al., 1999) . This work was extended by the group of Schreiber confirming the histone deacetylation activity of these constructs utilizing the same experimental conditions (Haggarty et al., 2003) . Furthermore, they show that HDAC6 wt and HDAC6 H216A are able to deacetylate MAP-stabilized microtubules polymerized from MAP-rich tubulin fraction, whereas HDAC6 H611A and HDAC6 H216/611A are incapable of deacetylating tubulin, indicating that the first deacetylation domain contains histone (and global) deacetylation activity and the second domain is tubulin as well as histone deacetylation activity. In contrast, the group of Patrick Matthias showed in 2003 that single mutations in either of the two deacetylation domains inhibit tubulin and histone deacetylation (Zhang et al., 2003) . In these experiments, immunoprecipitated HDAC6 constructs and [ 3 H]-acetyl-labeled peptide from human α-tubulin (amino acids 33-46) and acetyl-[ 3 H]-labeled peptide from human histone H4 were used. Furthermore, Zhang et al. demonstrate that multiple mutations in either of the two deacetylation domains (HDAC6 D250/252N//H254/255V and HDAC6 D648N//H650/651V) abolish tubulin and histone deacetylation utilizing the same experimental setup (Zhang et al., 2006) . Thus, Zhang et al reasoned that both domains are necessary for HDAC6 deacetylation ability. A third independent study from Zou et al. demonstrate that only HDAC6 wt and HDAC6 H216A show tubulin and histone deacetylaction ability, whereas HDAC6 H611A and HDAC6 H216/611A are not active (Zou et al., 2006) . In this experiment, HDAC6 was expressed in a baculovirus system and the substrates tubulin and histone were isolated from cells. Zou et al. concluded that only the second deacetylation domain contains deacetylation activity. These data are summarized in Supplementary Fig. 6D . Fig. 4B 
The authors have also themselves tested the TDAC activity of their mutants shown in
and C. The approach used is the ectopic expression of HDAC6 (wt and mutants) and the measurement of tubulin acetylation by western blot, which is far from being a sensitive and conclusive assay. Blots show modest effects and quantifications based on blots are questionable.Since the authors make such a strong case in excluding a role for tubulin-deacetylation in the HDAC6-stimulated migration of endothelial cells, it becomes very important to carefully control this point.
The western blot is not a sensitive and reliable method to measure HDAC6 catalytic activity. Signals are often saturated and the normalizations are not reliable.
In order to support a role for HDAC6 in cortactindeacetylation but not in tubulin deacetylation, the authors should set up convincing assays and show the activity of wt HDAC6 and their mutants towards both tubulin and cortactin.
To streamline our presentation and to avoid the comparison between single versus multiple mutations, we focused on single mutations in either or both of the deacetylation domains (HDAC6 H216/611A series). With regard to Figure 4B /C, we noticed that inhibition of HDAC6 by tubacin (10 µM) leads to a 25-fold increase of the acetylation of α-tubulin in HUVEC (Supplementary Figure 5A and B) indicating that under basal condition the majority of tubulin is already deacetylated. Based on these data, we hypothesized that this is the reason why overexpression of HDAC6 constructs does only modestly affect the α-tubulin acetylation under basal conditions. However, overexpression of some of these constructs (namely HDAC6 wt, HDAC6 H216A and HDAC6 H611A) significantly increases endothelial sprouting ( Figure 4E ) and the deacetylation of cortactin under basal conditions ( Figure 5D of the revised manuscript). Therefore, it is more likely that the regulation of angiogenesis is mediated by deacetylation of cortactin rather than by tubulin. To confirm the activity of these constructs towards α-tubulin, we changed the experimental settings. Therefore, we inhibited HDAC6 in HUVEC by 2.5 µM tubacin and determined in a pilot experiment the kinetics of tubulin deacetylation after washout of the inhibitor. Within 3 h the acetylation of α-tubulin is completely gone (Figure 3 for the reviewer). We repeated the experiment with HUVEC overexpressing different HDAC6 constructs, taking lysates at 90 min. HUVEC overexpressing HDAC6 wt and HDAC6 H216A show an increased deacetylation of tubulin at 90 min compared to mock transduced cells, confirming that HDAC6 wt and HDAC6 H216A exhibit α-tubulin deacetylation activity ( Figure 4C and Supplementary Fig. 6E ). Furthermore, HUVEC overexpressing HDAC6 H611A and HDAC6 H216/611A show an increased α-tubulin acetylation compared to mock transduced cells, indicating that these constructs are α-tubulin deacetylation dead and inhibit deacetylation by endogenous HDAC6 by competing against endogenous HDAC6 for acetylated tubulin.
Our study is the first to our knowledge which determines the influence of the different mutants in intact endothelial cells.
2) Since the authors have access to HDAC6 ko mice, it is not understandable that they made such a limited use of the system. They should have carefully analyzed vessel formation and angiogenesis in the mouse. At least, they need to test the role of HDAC6 in the tumor-induced angiogenesis using this model. This would have a very important impact on the role of HDAC6 in tumor biology.
We completely agree with the reviewer. To confirm our results, we evaluated neovacularization after hind limb ischemia in HDAC6 knockout mice. As shown in Figures 3H and I , HDAC6 knockout mice showed a reduced number of capillaries in the thigh muscle as well as in the lower leg compared to wild-type controls. In addition, we analyzed the retinal vessel outgrowth in HDAC6 knockout mice. In line with the previous finding that HDAC6 knockout mice develop normally, we did not observe a regulation of retinal vessel outgrowth (Figure 4 for the reviewer), indicating that developmental angiogenesis in mouse is not affected by HDAC6.
As suggested by the reviewer, we additionally analyzed tumor growth and tumor vascularization in a lewis lung carcinoma model in global HDAC6 knockout mice. Unexpectedly, tumor growth was increased in HDAC6 male knockout mice. However, angiogenesis as measured by quantifying endomucin-positive vessels was not affected in HDAC6-/-versus wt mice ( Figure 5 for the reviewer). Since HDAC6 was implicated in estrogen signaling and breast cancer (Azuma et al., 2009) , we additionally reproduced this study in female mice. However, consistent with the results seen in male mice, female HDAC6 knockout mice showed an increased tumor growth. Again, angiogenesis was not affected (Figure 6 for the reviewer). These data suggest that in mice lacking HDAC6, tumor growth by subcutaneously injected lewis lung carcinoma cells is promoted, whereas angiogenesis is not affected. Lee et al. demonstrated that HDAC6 is required for efficient oncogenic tumorigenesis and that HDAC6 knockout mice show a reduced number of skin tumors in a chemical carcinogen induced tumor model (Lee et al., 2008) . However to our knowledge there is no study regarding the effect of HDAC6 deficiency in the host regulating tumor growth and tumor vascularization of implanted wild-type tumors. Our experiments might be explained by a function of HDAC6 in the tumor environment e.g. in inflammatory cells, which are key regulators of tumor growth. Indeed, in comparison to endothelial cells, HDAC6 mRNA is 2.4 and 2.7-fold higher expressed in CD3+ lymphocytes and CD14+ myeloid cells ( Figure 5E for the reviewer). Whereas previous studies clearly document a function of HDAC6 in lymphocytes (Cabrero et al., 2006; de Zoeten et al., 2011; Serrador et al., 2004) , the role in myeloid cells is unclear and deserves further studies. Therefore, one may speculate that the deficiency of HDAC6 may modulate lymphocyte/myeloid cell functions to change the tumor environment. Therefore, we removed our statement: "Notably, inhibition of HDAC6 may additionally interfere with cancer growth and metastasis as it has been shown in skin cancers." Unfortunately, we do not have floxed mice available at present to investigate the specific contribution of HDAC6 in different cell types to the tumor growth.
3) The previous work of one the co-authors on the role of cortactin acetylation, is misleadingly presented. Indeed, Ed Seto and collaborators (2007) had already shown and discussed the fact that cortactin acetylation-deacetylation by HDAC6 is a major determinant in the control of cell motility. It is not acceptable that the authors, although discussing different data of this article, avoid mentioning this specific aspect until the middle of discussion section. The authors should change their presentation to make this point clear from the beginning.
As suggested by the reviewer, we described the role of HDAC6-mediated deacetylation of cortactin for cell migration in the introduction (page 4, para 1): "HDAC6 is a major determinant in the control of cell motility by regulation of the tubulin as well as the actin network (Gao et al, 2007 , Zhang et al, 2007 . HDAC6 regulates the binding of cortactin to actin in a deacetylation-dependent manner and thereby controls the branching of the actin network at the leading edge of cells (Zhang et al, 2007) ."
Minor points 4) The up-regulation of HDAC6 by hypoxia appears modest and is presented in a very short section. This section, which is unrelated to the other parts of the manuscript, could be discussed as "not shown" in the discussion section.
5) Kawaguchi et al. 2003, is not an appropriate reference for the ubiquitin-binding activity of HDAC6, which had been shown by two independent groups before this publication.
We changed the citation to " (Hook et al., 2002; Seigneurin-Berny et al., 2001 )".
6) The first paragraph of introduction on the role of HDACs in the control of chromatin/transcription is irrelevant. It is now clear that protein acetylation constitutes a general cellular signaling process controlling various cellular events (including cytoplasmic ones
) and reviews on the subject exist. Therefore, it would be better to avoid repeating the old introductory elements.
As suggested by the reviewer, we modified the introduction as follows (page 3, para 1): "Histone deacetylases (HDACs) are known repressors of gene transcription by deacetylating histone proteins favoring condensation of chromatin structure (for review see (Narlikar et al., 2002) ). Interestingly, HDACs remove acetyl groups from lysine residues of both histone and non-histone proteins, thereby affecting protein stability, activity and binding affinity as recently described (Bolden et al., 2006; Choudhary et al., 2009; Spange et al., 2009) .The HDAC family consists of four classes : Class I (HDAC1, 2, 3, 8), class II (class IIa: HDAC4, 5, 7, 9; class IIb: HDAC6 and 10) , class III (Sirtuin 1-7), and class IV (HDAC 11) ."
Reply to reviewer #3:
We thank the reviewer for her / his helpful suggestions. To test a possible compensatory role of HDAC10 for HDAC6 in deacetylation of cortactin and modulating angiogenesis, we silenced HDAC10 with siRNA in HUVEC ( Figure 7A for the reviewer). As shown in Figure 7B for the reviewer, silencing of HDAC10 does not affect endothelial cell sprouting, indicating that HDAC10 does not regulate sprouting angiogenesis under basal conditions. Furthermore, silencing of HDAC10 does not increase the acetylation of cortactin ( Figure  7C for the reviewer). However, overexpression of Danio rerio HDAC10 mRNA in the developing zebrafish rescues in part the vessel defects by HDAC6 depletion ( Figure 7D -G for the reviewer). It is conceivable that the compensation for HDAC6 by HDAC10 is cell type-or species-specific. Furthermore, it might be that silencing of HDAC10 does only affect sprouting of HUVEC and cortactin acetylation if endogenous HDAC6 is not present. Therefore, one should analyze whether double knockdown of HDAC6 and HDAC10 shows an additive effect for sprouting angiogenesis (like the reviewer suggested with double knockout mice) or if overexpression of HDAC10 rescues the sprouting defect of HDAC6 depletion in HUVEC.
Kaluza
Formally, we additionally can not exclude that other HDACs interacts with cortactin in endothelial cells which might compensate for HDAC6. It was shown that Sirt1 and Sirt2 deacetylate cortactin in ovarian cancer cells and in HeLa cells (Zhang et al., 2007; Zhang et al., 2009) . In HUVEC, inhibition of sirtuins by nicotinamide does not affect the acetylation of cortactin ( Figure 5F ). However, it is conceivable that in endothelial cells from a different origin sirtuins or other HDACs might regulate the acetylation of cortactin and might compensate for the loss of HDAC6. Unfortunately, it was not possible to test this hypothesis in the given time since we have no access to knockout mice lacking several HDACs. According to the reviewer's suggestion, we replaced the cell images showing higher magnifications to confirm the co-localization of HDAC6 with cortactin as well as F-actin with HDAC6 and cortactin ( Figure 5A and Supplementary Figure 7) . For the co-localization of HDAC6 with cortactin and HDAC6 with F-actin at the cell membrane, we additionally show enlarged pictures of the leading edge of HUVEC ( Figure 5A and Supplementary Figure 7) . As suggested, we show immunofluorescence images of untransfected, siScr transfected and siHDAC6 transfected cells in Figure 7 for the reviewer. The HDAC6 siRNA strongly decreased immunofluorescence detected with an HDAC6 specific antibody, demonstrating the specificity of the antibody used for the immunostaining.
3) To prove the real substrate of HDAC6 is cortactin that accounts for the defects of blood vessels in
HDAC6 morphants, the authors should perform the rescue experiment using cortactin 9KR in HDAC6 morphants.
As suggested by the reviewer, we performed a rescue experiment using cortactin 9KR mutant in zebrafish depleted for HDAC6 by morpholino. Indeed, overexpression of cortactin 9KR rescues in part the vessel defects of HDAC6 depletion ( Figure 6H and Supplementary Fig. 11 ) indicating that cortactin is also a target of HDAC6 in zebrafish endothelial cells. Figure 2A According to the reviewer's suggestion, we moved this figure to supplementary Figure 4C .
4) Minor points: (i)
(ii) Why did the authors need to immunostain fli1:egfpTg fish using anti-GFP antibody instead of directly visualizing the green fluorescence? The original GFP images should be shown as the results.
We used the GFP-antibody staining in zebrafish to avoid photo bleaching of the GFP signal, which can appear if the green fluorescence is directly visualized. This might create false positive vessel defects. Technically, it is hard to differentiate the two vessel layers by fluorescence microscopy. This would require confocal fluorescence microscopy, which is relatively time consuming for hundreds of embryos. Figure 2C ? The order should be CoMo 5 ng, according to the orders in other Figures (Figure 2C, 2F and 2G) .
(iii) Why did the author change the order of loading samples in
We changed the order of the samples in the original Figure 2C (now Figure 2B of the revised manuscript).
(iv) Figure 3H, in the legend, the authors describe that this is representative image. What is this representative of?
We changed the figure legend to: "H) Representative images of invaded lectin-positive vessels into the matrigel plug." (v) Figure 3I (the image of H&E staining) should be enlarged; otherwise the readers cannot distinguish the H-stained cells in the E-stained matrigel.
According to the reviewer's recommendation, we enlarged the images.
(vi) The readers can not see the nuclei stained with DAPI.
We included new images with a more intense staining using Hoechst 33342 instead of DAPI. 
Retina model:
Eyes of HDAC6 -/-or HDAC6 +/+ littermates at day P5 were removed and the eyes were fixed for 2h with 4% formaldehyde on ice. After 3 times washing the retina was dissected and the hyaloid vessels were removed. The retinas were washed with PBlec buffer for 20 min and incubated in direct conjugated isolectin-B4 (Invitrogen #I21411 500 μg / 500 μl PBlec) 1:100 in PBlec overnight at 4 C. Retinas were washed in PBS, post-fixed in 4% formaldehyde for 5 min and mounted for microscopic analysis. Pictures were taken using laser scanning microscope (LSM510 META with Software Release 4.0 SP2, Carl Zeiss, Jena).
EMBOJ-2011-77252R (A-C: n=4 for HDAC6+/+ and n=6 for HDAC6-/-) D) Tumor angiogenesis was detected in sections stained with the endothelial marker endomucin. A secondary antibody conjugated to Alexa Fluor 488 was used. The number of vessels was counted manually (n=4 for HDAC6+/+ and n=4 for HDAC6-/-). E) mRNA Expression of HDAC6 in cultured HUVEC and human CD3 + and CD14 + isolated from blood. RNA was isolated, reverse transcribed and used for real-time PCR. Expression was normalized to total RNA (n=3-4).
Tumor model:
Lewis Lung Carcinoma cells (LLC1, ATCC CRL-1642) were cultured in DMEM containing Glutamax™ and sodium pyruvate (Invitrogen) supplemented with 10% FCS and Penicillin/Streptomycin (P/S, Roche). 1 million LLC cells were injected subcutaneously in 3 to 4 month old HDAC6 +/+ or HDAC6 -/-mice. Tumor volume was measured at the indicated time points with a Thorpe caliper (Horex, Germany) and was calculated as d1 x d2. After explantation, tumors were weighted and 3D tumor volume was calculated using the formula: volume = [1/2*(L*W 2 )], where L is length of the tumor and W is width of tumor. Tumor specimens were fixed in 4% formalin and were histologically examined. Sections were stained with an anti-endomucin antibody (eBioscience; 1:100) followed by an anti-rat Alexa Fluor 488 antibody (Invitrogen). Pictures were taken with a laser scanning microscope (LSM510 META with Software Release 4.0 SP2, Carl Zeiss, Jena) using the Plan-Neofluar 40x/1.3 Oil objective. 5 images per tumor were evaluated manually. EMBOJ-2011-77252R A) Relative mRNA expression of HDAC10 24 h after transfection with siHDAC10 or control siRNA in HUVEC. Data were normalized to RPLP0 expression (n=4). B) Capillary-like sprouting from HUVEC spheroids was measured after HDAC10 silencing. The spheroid assay was performed 24 h after siRNA transfection. Data are shown as cumulative sprout length per spheroid (n=3). C) HUVEC were stably transduced with V5-tagged cortactin wt virus followed by HDAC10 or control siRNA transfection for 72 h. Equal amounts of protein lysate were subjected to immunoprecipitation reaction with anti-acetyllysine antibody conjugated to agarose beads. Bound proteins were resolved and used for Western blot analysis of cortactin acetylation levels utilizing anti-cortactin specific antibody. HDAC10 and acetylated α-tubulin levels were measured in total cell lysates. As loading controls serve α-tubulin, HDAC6 and cortactin-V5 expression in total cell lysates before precipitation (n=3). D) Danio rerio HDAC10 cDNA clone in pME18S-FL was obtained from Imagene (clone BC044446 corresponding NM_199775.1) and subcloned in pCS2plus using EcoRI and XbaI. For in vitro transcription, the vector was KpnI-linearized and sense mRNA was transcribed using SP6 promotor. Quality of mRNA was controlled on a denaturating RNA gel with a main band at approximately 2800bp. E-F) Quantification of vessel defects in ATG-HDAC6-morphants with or without 100 pg of Danio rerio HDAC10-mRNA 48 h post fertilization. As control group serves 100 pg of HDAC10-mRNA (n=69 for ATG-HDAC6-Mo; n=55 for ATG-HDAC6-Mo + HDAC10-mRNA; n=52 for HDAC10-mRNA) E) Quantification of ISV and DLAV defects. There are a few minor format/textural issues that we need to resolve: 2) the last lane in fig 4B was removed -I appreciate this was likely in response to ref 1, but I would like to be reminded of the rationale.
3) More importantly, a number of key issues raised by the referees, namely ref.
2's request for in vivo work and ref 3's point 1, were addressed successfully experimentally, but the figures were only displayed 'for referees'. Since this was a core part of the revision and since this data significantly adds to the depth and scope of the study we would like to request addition of this data into the main paper (be it embedded in the main figures, or supplementary figures). We would encourage you to integrate the SI figures into far fewer multipanel figure, to avoid having too many supplementary items (as you know, an issue under intense discussion in the community at present).
4) As you know, we will start to integrate uncropped versions of key blots and gels in a single supplementary file. We would like to invite you to be the first paper at EMBO J that accomplishes this, as this would set a great precedent! Please contact me if you would like to discuss which panels to include. The SI figure simply needs basic information to point to the appropriate panel in the main paper and no further annotation; however, the uncropped figures must include labelled MW markers (which are entirely absent from your current figure panels!).
We would like to fast track publication, given the Li et al. paper, so please aim to re-submit the manuscript as soon as possible and alert me when it arrives.
Please bear in mind that you referee response will form part of the Review Process File, and will therefore be available online to the community. For more details on our Transparent Editorial Process, please visit our website: http://www.nature.com/emboj/about/process.html yours sincerely,
Editor
------------------------------------------------REFEREE COMMENTS
Referee #1 (Remarks to the Author):
The authors have taken care adequately of my previous comments, as well as of the comments from the other reviewers.
Referee #2 (Remarks to the Author):
Data are now mostly clear-cut and convincing and most of the questions and concerns raised previously have been taken into account. I can therefore recommend this manuscript for publication.
Referee #3 (Remarks to the Author):
In the revised manuscript, most of the critical comments have been addressed. I just find a few problems that can be corrected by minor revision.
1. The authors tried to change the order of the samples by just cutting the frame from the original immunoblot. This kind of assembly of the fragmented pieces should not be accepted. They need to do new experiments to show the perfect blot.
2. In the legend of Figure 1 , "Nuclei are stained with Hoechst 33342 in blue". However, in the Figure 1A , title is still DAPI. Did the authors really use Hoechst? If they really used Hoechst, please check all the figures and supplementary figures in which "DAPI" is indicated.
2nd Revision -authors' response 19 July 2011
Reply to reviewer #3:
We thank the reviewer for her / his helpful suggestions. As suggested by the reviewer during the first revision, we changed the order of the samples in Figure 2B of the revised manuscript. In addition, we now provided the uncropped version of Figure 2B as original data. Figure 1 , "Nuclei are stained with Hoechst 33342 in blue". However, in the Figure 1A, We apologize for the mislabeling of some figures with respect to the dye used for the nuclear staining. We changed Figure 1A , 5A, Supplementary Figure 6A and B (former Supplementary Figure 7A and B) replacing "DAPI" with "Nucleus". Nuclei were stained with Hoechst 33342 as described in the figure legend of the respective figures.
In the legend of
